Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Wall Street's top stories for Monday » 16:12
11/23/20
11/23
16:12
11/23/20
16:12
AZN

AstraZeneca

$54.62 /

-0.67 (-1.21%)

, REGN

Regeneron

$523.05 /

+3.48 (+0.67%)

, MRK

Merck

$80.30 /

-0.14 (-0.17%)

, BLNK

Blink Charging

$33.77 /

+11.14 (+49.23%)

, RESI

Front Yard Residential

$16.34 /

+2.945 (+21.99%)

, ARES

Ares Management

$44.78 /

-0.24 (-0.53%)

, K

Kellogg

$63.63 /

-1.34 (-2.06%)

, HMI

Huami

$13.59 /

-1.15 (-7.80%)

The major averages began…

ShowHide Related Items >><<
RESI Front Yard Residential
$16.34 /

+2.945 (+21.99%)

REGN Regeneron
$523.05 /

+3.48 (+0.67%)

MRK Merck
$80.30 /

-0.14 (-0.17%)

K Kellogg
$63.63 /

-1.34 (-2.06%)

HMI Huami
$13.59 /

-1.15 (-7.80%)

BLNK Blink Charging
$33.77 /

+11.14 (+49.23%)

AZN AstraZeneca
$54.62 /

-0.67 (-1.21%)

ARES Ares Management
$44.78 /

-0.24 (-0.53%)

AZN AstraZeneca
$54.62 /

-0.67 (-1.21%)

11/23/20 Morgan Stanley
AstraZeneca price target raised to 9,400 GBp from 9,000 GBp at Morgan Stanley
11/23/20 SVB Leerink
AstraZeneca vaccine 'will never be licensed in the U.S.,' says SVB Leerink
11/11/20 Oppenheimer
Amgen price target raised to $280 from $275 at Oppenheimer
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
REGN Regeneron
$523.05 /

+3.48 (+0.67%)

11/23/20 Piper Sandler
Regeneron Covid cocktail could be meaningful to earnings, says Piper Sandler
11/11/20 Truist
Opthea initiated with a Buy at Truist
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
11/06/20 Truist
Regeneron price target raised to $770 from $750 at Truist
MRK Merck
$80.30 /

-0.14 (-0.17%)

11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
10/23/20
Fly Intel: Pre-market Movers
BLNK Blink Charging
$33.77 /

+11.14 (+49.23%)

08/14/20
Fly Intel: Top five analyst downgrades
08/14/20 H.C. Wainwright
Blink Charging downgraded to Neutral from Buy at H.C. Wainwright
RESI Front Yard Residential
$16.34 /

+2.945 (+21.99%)

10/20/20
Fly Intel: Top five analyst downgrades
10/20/20 Northland
Front Yard Residential downgraded to Market Perform from Outperform at Northland
10/20/20 JMP Securities
Front Yard Residential downgraded to Market Perform from Outperform at JMP Securities
10/20/20 Credit Suisse
Front Yard Residential downgraded to Neutral from Outperform at Credit Suisse
ARES Ares Management
$44.78 /

-0.24 (-0.53%)

05/28/20 BMO Capital
Ares Management upgraded to Outperform from Market Perform at BMO Capital
04/15/20 Wells Fargo
Ares Management price target lowered to $41 from $50 at Wells Fargo
02/18/20 RBC Capital
Ares Management price target raised to $45 from $38 at RBC Capital
02/18/20 BMO Capital
Ares Management price target raised to $41 from $34 at BMO Capital
K Kellogg
$63.63 /

-1.34 (-2.06%)

11/23/20
Fly Intel: Top five analyst downgrades
11/23/20 Credit Suisse
Credit Suisse downgrades Kellogg ahead of 'disappointing guidance'
11/23/20 Credit Suisse
Kellogg downgraded to Neutral from Outperform at Credit Suisse
10/06/20 Piper Sandler
Piper teen survey shows Snap, Amazon and Apple remain favorites
HMI Huami
$13.59 /

-1.15 (-7.80%)

05:27 Today Credit Suisse
Huami downgraded to Neutral from Outperform at Credit Suisse
RESI Front Yard Residential
$16.34 /

+2.945 (+21.99%)

REGN Regeneron
$523.05 /

+3.48 (+0.67%)

MRK Merck
$80.30 /

-0.14 (-0.17%)

K Kellogg
$63.63 /

-1.34 (-2.06%)

HMI Huami
$13.59 /

-1.15 (-7.80%)

BLNK Blink Charging
$33.77 /

+11.14 (+49.23%)

AZN AstraZeneca
$54.62 /

-0.67 (-1.21%)

ARES Ares Management
$44.78 /

-0.24 (-0.53%)

  • 27
    May
REGN Regeneron
$523.05 /

+3.48 (+0.67%)

MRK Merck
$80.30 /

-0.14 (-0.17%)

K Kellogg
$63.63 /

-1.34 (-2.06%)

BLNK Blink Charging
$33.77 /

+11.14 (+49.23%)

AZN AstraZeneca
$54.62 /

-0.67 (-1.21%)

RESI Front Yard Residential
$16.34 /

+2.945 (+21.99%)

REGN Regeneron
$523.05 /

+3.48 (+0.67%)

MRK Merck
$80.30 /

-0.14 (-0.17%)

K Kellogg
$63.63 /

-1.34 (-2.06%)

BLNK Blink Charging
$33.77 /

+11.14 (+49.23%)

AZN AstraZeneca
$54.62 /

-0.67 (-1.21%)

REGN Regeneron
$523.05 /

+3.48 (+0.67%)

MRK Merck
$80.30 /

-0.14 (-0.17%)

BLNK Blink Charging
$33.77 /

+11.14 (+49.23%)

AZN AstraZeneca
$54.62 /

-0.67 (-1.21%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:18
11/23/20
11/23
12:18
11/23/20
12:18
AZN

AstraZeneca

$53.68 /

-1.61 (-2.91%)

, REGN

Regeneron

$518.00 /

-1.57 (-0.30%)

, MRK

Merck

$80.06 /

-0.38 (-0.47%)

, BLNK

Blink Charging

$29.57 /

+6.94 (+30.67%)

, RESI

Front Yard Residential

$16.38 /

+2.98 (+22.25%)

, ARES

Ares Management

$44.95 /

-0.07 (-0.16%)

, K

Kellogg

$63.81 /

-1.16 (-1.79%)

, HMI

Huami

$13.64 /

-1.1 (-7.46%)

The major averages are…

ShowHide Related Items >><<
RESI Front Yard Residential
$16.38 /

+2.98 (+22.25%)

REGN Regeneron
$518.00 /

-1.57 (-0.30%)

MRK Merck
$80.06 /

-0.38 (-0.47%)

K Kellogg
$63.81 /

-1.16 (-1.79%)

HMI Huami
$13.64 /

-1.1 (-7.46%)

BLNK Blink Charging
$29.57 /

+6.94 (+30.67%)

AZN AstraZeneca
$53.68 /

-1.61 (-2.91%)

ARES Ares Management
$44.95 /

-0.07 (-0.16%)

AZN AstraZeneca
$53.68 /

-1.61 (-2.91%)

11/23/20 Morgan Stanley
AstraZeneca price target raised to 9,400 GBp from 9,000 GBp at Morgan Stanley
11/23/20 SVB Leerink
AstraZeneca vaccine 'will never be licensed in the U.S.,' says SVB Leerink
11/11/20 Oppenheimer
Amgen price target raised to $280 from $275 at Oppenheimer
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
REGN Regeneron
$518.00 /

-1.57 (-0.30%)

11/23/20 Piper Sandler
Regeneron Covid cocktail could be meaningful to earnings, says Piper Sandler
11/11/20 Truist
Opthea initiated with a Buy at Truist
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
11/06/20 Truist
Regeneron price target raised to $770 from $750 at Truist
MRK Merck
$80.06 /

-0.38 (-0.47%)

11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
10/23/20
Fly Intel: Pre-market Movers
BLNK Blink Charging
$29.57 /

+6.94 (+30.67%)

08/14/20
Fly Intel: Top five analyst downgrades
08/14/20 H.C. Wainwright
Blink Charging downgraded to Neutral from Buy at H.C. Wainwright
RESI Front Yard Residential
$16.38 /

+2.98 (+22.25%)

10/20/20
Fly Intel: Top five analyst downgrades
10/20/20 Northland
Front Yard Residential downgraded to Market Perform from Outperform at Northland
10/20/20 JMP Securities
Front Yard Residential downgraded to Market Perform from Outperform at JMP Securities
10/20/20 Credit Suisse
Front Yard Residential downgraded to Neutral from Outperform at Credit Suisse
ARES Ares Management
$44.95 /

-0.07 (-0.16%)

05/28/20 BMO Capital
Ares Management upgraded to Outperform from Market Perform at BMO Capital
04/15/20 Wells Fargo
Ares Management price target lowered to $41 from $50 at Wells Fargo
02/18/20 RBC Capital
Ares Management price target raised to $45 from $38 at RBC Capital
02/18/20 BMO Capital
Ares Management price target raised to $41 from $34 at BMO Capital
K Kellogg
$63.81 /

-1.16 (-1.79%)

11/23/20
Fly Intel: Top five analyst downgrades
11/23/20 Credit Suisse
Credit Suisse downgrades Kellogg ahead of 'disappointing guidance'
11/23/20 Credit Suisse
Kellogg downgraded to Neutral from Outperform at Credit Suisse
10/06/20 Piper Sandler
Piper teen survey shows Snap, Amazon and Apple remain favorites
HMI Huami
$13.64 /

-1.1 (-7.46%)

RESI Front Yard Residential
$16.38 /

+2.98 (+22.25%)

REGN Regeneron
$518.00 /

-1.57 (-0.30%)

MRK Merck
$80.06 /

-0.38 (-0.47%)

K Kellogg
$63.81 /

-1.16 (-1.79%)

HMI Huami
$13.64 /

-1.1 (-7.46%)

BLNK Blink Charging
$29.57 /

+6.94 (+30.67%)

AZN AstraZeneca
$53.68 /

-1.61 (-2.91%)

ARES Ares Management
$44.95 /

-0.07 (-0.16%)

  • 27
    May
REGN Regeneron
$518.00 /

-1.57 (-0.30%)

MRK Merck
$80.06 /

-0.38 (-0.47%)

K Kellogg
$63.81 /

-1.16 (-1.79%)

BLNK Blink Charging
$29.57 /

+6.94 (+30.67%)

AZN AstraZeneca
$53.68 /

-1.61 (-2.91%)

RESI Front Yard Residential
$16.38 /

+2.98 (+22.25%)

REGN Regeneron
$518.00 /

-1.57 (-0.30%)

MRK Merck
$80.06 /

-0.38 (-0.47%)

K Kellogg
$63.81 /

-1.16 (-1.79%)

BLNK Blink Charging
$29.57 /

+6.94 (+30.67%)

AZN AstraZeneca
$53.68 /

-1.61 (-2.91%)

REGN Regeneron
$518.00 /

-1.57 (-0.30%)

MRK Merck
$80.06 /

-0.38 (-0.47%)

BLNK Blink Charging
$29.57 /

+6.94 (+30.67%)

AZN AstraZeneca
$53.68 /

-1.61 (-2.91%)

Conference/Events
Cantor Fitzgerald biopharma analysts to hold analyst/industry conference call » 10:25
11/23/20
11/23
10:25
11/23/20
10:25
GILD

Gilead

$59.85 /

-0.25 (-0.42%)

, LLY

Eli Lilly

$143.43 /

-2.21 (-1.52%)

, REGN

Regeneron

$521.45 /

+1.88 (+0.36%)

, HGEN

Humanigen

$8.72 /

-0.15 (-1.69%)

Biopharmaceuticals…

Biopharmaceuticals Analysts Chen & Kim and Biotechnology Analyst Young, along with Gerald Pier, PhD, Professor of Medicine, Microbiology & Immunology at Harvard Medical School, discuss Monoclonal Antibodies to treat COVID-19 on an Analyst/Industry conference call to be held on November 23 at 11 am.

ShowHide Related Items >><<
REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

11/20/20 Raymond James
Use of Gilead's remdesivir likely to skew to U.S. into Q1, says Raymond James
11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Morgan Stanley
Gilead resumed with an Equal Weight at Morgan Stanley
10/29/20 BMO Capital
Gilead price target lowered to $64 from $74 at BMO Capital
LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

11/20/20 Stifel
Precision BioSciences price target raised to $22 from $21 at Stifel
11/17/20 Mizuho
Eli Lilly price target lowered to $156 from $164 at Mizuho
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform, $150 price target at Bernstein
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform at Bernstein
REGN Regeneron
$521.45 /

+1.88 (+0.36%)

11/23/20 Piper Sandler
Regeneron Covid cocktail could be meaningful to earnings, says Piper Sandler
11/11/20 Truist
Opthea initiated with a Buy at Truist
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
11/06/20 Truist
Regeneron price target raised to $770 from $750 at Truist
HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

11/06/20 H.C. Wainwright
Humanigen price target raised to $34 from $31 at H.C. Wainwright
10/21/20
Fly Intel: Top five analyst initiations
10/21/20 Cantor Fitzgerald
Humanigen initiated with an Overweight at Cantor Fitzgerald
10/20/20 Cantor Fitzgerald
Humanigen initiated with an Overweight at Cantor Fitzgerald
REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

  • 18
    Sep
  • 27
    May
REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

On The Fly
Fly Intel: Pre-market Movers » 08:54
11/23/20
11/23
08:54
11/23/20
08:54
IDEX

Ideanomics

$1.54 /

+0.34 (+28.33%)

, REGN

Regeneron

$519.36 /

+4.81 (+0.93%)

, HMI

Huami

$14.74 /

-0.48 (-3.15%)

, KFY

Korn/Ferry

$38.23 /

-0.35 (-0.91%)

, TWST

Twist Bioscience

$115.56 /

+1.02 (+0.89%)

, HCDI

Harbor Custom Development

$4.50 /

-0.06 (-1.32%)

, BZUN

Baozun

$41.88 /

+1.1 (+2.70%)

, BLRX

BioLineRx

$2.60 /

+0.29 (+12.55%)

, AZN

AstraZeneca

$55.29 /

+1.27 (+2.35%)

, K

Kellogg

$64.97 /

-0.23 (-0.35%)

Check out this morning's…

ShowHide Related Items >><<
TWST Twist Bioscience
$115.56 /

+1.02 (+0.89%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

KFY Korn/Ferry
$38.23 /

-0.35 (-0.91%)

K Kellogg
$64.97 /

-0.23 (-0.35%)

IDEX Ideanomics
$1.54 /

+0.34 (+28.33%)

HMI Huami
$14.74 /

-0.48 (-3.15%)

HCDI Harbor Custom Development
$4.50 /

-0.06 (-1.32%)

BZUN Baozun
$41.88 /

+1.1 (+2.70%)

BLRX BioLineRx
$2.60 /

+0.29 (+12.55%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

IDEX Ideanomics
$1.54 /

+0.34 (+28.33%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

11/23/20 Piper Sandler
Regeneron Covid cocktail could be meaningful to earnings, says Piper Sandler
11/11/20 Truist
Opthea initiated with a Buy at Truist
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
11/06/20 Truist
Regeneron price target raised to $770 from $750 at Truist
HMI Huami
$14.74 /

-0.48 (-3.15%)

KFY Korn/Ferry
$38.23 /

-0.35 (-0.91%)

08/24/20 Truist
Korn/Ferry price target lowered to $34 from $37 at Truist
07/16/20 Sidoti
Korn/Ferry upgraded to Buy from Neutral at Sidoti
06/08/20 Sidoti
Korn/Ferry downgraded to Neutral from Buy at Sidoti
05/21/20 Credit Suisse
Korn/Ferry upgraded to Neutral on valuation at Credit Suisse
TWST Twist Bioscience
$115.56 /

+1.02 (+0.89%)

10/20/20 SVB Leerink
Twist Bioscience initiated with a Market Perform at SVB Leerink
02/06/20 Cowen
Developments in Agilent-Twist dispute could mean settlement imminent, says Cowen
HCDI Harbor Custom Development
$4.50 /

-0.06 (-1.32%)

BZUN Baozun
$41.88 /

+1.1 (+2.70%)

08/25/20 86 Research
Baozun initiated with a Hold at 86 Research
08/24/20 Citi
Baozun price target raised to $50 from $43 at Citi
06/03/20 Credit Suisse
Baozun upgraded to Outperform from Neutral at Credit Suisse
03/31/20 BofA
Baozun downgraded to Neutral on slowing near-term growth at BofA
BLRX BioLineRx
$2.60 /

+0.29 (+12.55%)

03/13/20 Oppenheimer
BioLineRx price target lowered to $11 from $26 at Oppenheimer
AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

11/23/20 SVB Leerink
AstraZeneca vaccine 'will never be licensed in the U.S.,' says SVB Leerink
11/11/20 Oppenheimer
Amgen price target raised to $280 from $275 at Oppenheimer
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
K Kellogg
$64.97 /

-0.23 (-0.35%)

11/23/20 Credit Suisse
Credit Suisse downgrades Kellogg ahead of 'disappointing guidance'
11/23/20 Credit Suisse
Kellogg downgraded to Neutral from Outperform at Credit Suisse
10/06/20 Piper Sandler
Piper teen survey shows Snap, Amazon and Apple remain favorites
08/28/20
Fly Intel: Top five analyst initiations
TWST Twist Bioscience
$115.56 /

+1.02 (+0.89%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

KFY Korn/Ferry
$38.23 /

-0.35 (-0.91%)

K Kellogg
$64.97 /

-0.23 (-0.35%)

HMI Huami
$14.74 /

-0.48 (-3.15%)

HCDI Harbor Custom Development
$4.50 /

-0.06 (-1.32%)

BZUN Baozun
$41.88 /

+1.1 (+2.70%)

BLRX BioLineRx
$2.60 /

+0.29 (+12.55%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

  • 07
    Aug
  • 04
    Jun
  • 27
    May
  • 20
    Feb
REGN Regeneron
$519.36 /

+4.81 (+0.93%)

K Kellogg
$64.97 /

-0.23 (-0.35%)

IDEX Ideanomics
$1.54 /

+0.34 (+28.33%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

TWST Twist Bioscience
$115.56 /

+1.02 (+0.89%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

K Kellogg
$64.97 /

-0.23 (-0.35%)

IDEX Ideanomics
$1.54 /

+0.34 (+28.33%)

HCDI Harbor Custom Development
$4.50 /

-0.06 (-1.32%)

BZUN Baozun
$41.88 /

+1.1 (+2.70%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

IDEX Ideanomics
$1.54 /

+0.34 (+28.33%)

BZUN Baozun
$41.88 /

+1.1 (+2.70%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

Hot Stocks
Kiniksa announces FDA acceptance of sBLA, priority review for rilonacept » 08:12
11/23/20
11/23
08:12
11/23/20
08:12
KNSA

Kiniksa

$14.93 /

+0.05 (+0.34%)

, REGN

Regeneron

$519.36 /

+4.81 (+0.93%)

Kiniksa Pharmaceuticals…

Kiniksa Pharmaceuticals (KNSA) announced that the U.S. Food and Drug Administration accepted the supplemental Biologics License Application for rilonacept in recurrent pericarditis. The FDA granted priority review to the application and assigned a Prescription Drug User Fee Act goal date of March 21, 2021. Rilonacept is a weekly, subcutaneously-injected, recombinant dimeric fusion protein that blocks interleukin-1 alpha and interleukin-1 beta signaling. The FDA granted Breakthrough Therapy designation to rilonacept for the treatment of recurrent pericarditis in 2019 and Orphan Drug designation to rilonacept for the treatment of pericarditis in 2020. The regulatory submission was based on positive data from RHAPSODY, a pivotal Phase 3 trial of rilonacept in recurrent pericarditis. RHAPSODY met its prespecified primary and all major secondary efficacy endpoints, showing that rilonacept treatment in the trial improved clinically meaningful outcomes associated with the significant unmet medical need in recurrent pericarditis. RHAPSODY data were recently published in The New England Journal of Medicine simultaneously with a late-breaking scientific presentation at the American Heart Association's Scientific Sessions 2020. Rilonacept was discovered and developed by Regeneron Pharmaceuticals (REGN) and is approved by the FDA for the treatment of Cryopyrin-Associated Periodic Syndromes under the brand name ARCALYST. Kiniksa licensed rilonacept from Regeneron in 2017 for evaluation in diseases believed to be mediated by both IL-1alpha and IL-1beta, including recurrent pericarditis. Based on positive RHAPSODY data, the Biologic License Application for CAPS transferred to Kiniksa. If approved by the FDA for recurrent pericarditis, Kiniksa will take responsibility for sales and distribution of rilonacept for all the approved indications in the United States and evenly split profits with Regeneron, as described in the Rilonacept License Agreement. Kiniksa is obligated to pay regulatory milestones to Regeneron of up to an aggregate of $27.5M through the time of a potential approval of rilonacept in recurrent pericarditis, of which $7.5M is expected to be paid in the fourth quarter of 2020. Kiniksa continues to prepare for the potential commercial launch of rilonacept in recurrent pericarditis. The company has been generating evidence on disease burden, building disease awareness with payers, physicians, and advocacy groups, and establishing core capabilities such as distribution, patient services and data management.

ShowHide Related Items >><<
REGN Regeneron
$519.36 /

+4.81 (+0.93%)

KNSA Kiniksa
$14.93 /

+0.05 (+0.34%)

KNSA Kiniksa
$14.93 /

+0.05 (+0.34%)

10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
07/17/20 JPMorgan
Kiniksa risk/reward attractive into Phase 2 data, says JPMorgan
06/29/20 Goldman Sachs
Kiniksa price target raised to $33 from $29 at Goldman Sachs
06/29/20 Wedbush
Kiniksa price target raised to $38 from $30 at Wedbush
REGN Regeneron
$519.36 /

+4.81 (+0.93%)

11/23/20 Piper Sandler
Regeneron Covid cocktail could be meaningful to earnings, says Piper Sandler
11/11/20 Truist
Opthea initiated with a Buy at Truist
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
11/06/20 Truist
Regeneron price target raised to $770 from $750 at Truist
REGN Regeneron
$519.36 /

+4.81 (+0.93%)

KNSA Kiniksa
$14.93 /

+0.05 (+0.34%)

  • 22
    Jul
  • 27
    May
  • 14
    May
REGN Regeneron
$519.36 /

+4.81 (+0.93%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

KNSA Kiniksa
$14.93 /

+0.05 (+0.34%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

KNSA Kiniksa
$14.93 /

+0.05 (+0.34%)

Recommendations
Regeneron Covid cocktail could be meaningful to earnings, says Piper Sandler » 04:56
11/23/20
11/23
04:56
11/23/20
04:56
REGN

Regeneron

$519.36 /

+4.81 (+0.93%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals with a $675 price target after the FDA provided Emergency Use Authorization for REGN-COV2, the company's monoclonal antibody cocktail directed against SARS-CoV-2. The analyst, who admits the news came a little later than he expected, is encouraged that prior guidance of shipping the 300,000 dose BARDA order by end of January remains. Raymond believes the cocktail could be a meaningful earnings contributor and add $4 per share or more to Regeneron's 2021 earnings. He continues to believe this can be a "durable" $1B plus business.

ShowHide Related Items >><<
REGN Regeneron
$519.36 /

+4.81 (+0.93%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
11/06/20 Truist
Regeneron price target raised to $770 from $750 at Truist
11/05/20 Piper Sandler
Regeneron shares will continue moving higher, says Piper Sandler
REGN Regeneron
$519.36 /

+4.81 (+0.93%)

  • 27
    May
REGN Regeneron
$519.36 /

+4.81 (+0.93%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

Conference/Events
Cantor Fitzgerald biopharma analysts to hold analyst/industry conference call » 04:55
11/23/20
11/23
04:55
11/23/20
04:55
GILD

Gilead

$60.10 /

-0.53 (-0.87%)

, LLY

Eli Lilly

$145.62 /

+2.16 (+1.51%)

, REGN

Regeneron

$519.36 /

+4.81 (+0.93%)

, HGEN

Humanigen

$8.88 /

+0.61 (+7.38%)

Biopharmaceuticals…

Biopharmaceuticals Analysts Chen & Kim and Biotechnology Analyst Young, along with Gerald Pier, PhD, Professor of Medicine, Microbiology & Immunology at Harvard Medical School, discuss Monoclonal Antibodies to treat COVID-19 on an Analyst/Industry conference call to be held on November 23 at 11 am.

ShowHide Related Items >><<
REGN Regeneron
$519.36 /

+4.81 (+0.93%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

HGEN Humanigen
$8.88 /

+0.61 (+7.38%)

GILD Gilead
$60.10 /

-0.53 (-0.87%)

GILD Gilead
$60.10 /

-0.53 (-0.87%)

11/20/20 Raymond James
Use of Gilead's remdesivir likely to skew to U.S. into Q1, says Raymond James
11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Morgan Stanley
Gilead resumed with an Equal Weight at Morgan Stanley
10/29/20 BMO Capital
Gilead price target lowered to $64 from $74 at BMO Capital
LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

11/20/20 Stifel
Precision BioSciences price target raised to $22 from $21 at Stifel
11/17/20 Mizuho
Eli Lilly price target lowered to $156 from $164 at Mizuho
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform, $150 price target at Bernstein
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform at Bernstein
REGN Regeneron
$519.36 /

+4.81 (+0.93%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
11/06/20 Truist
Regeneron price target raised to $770 from $750 at Truist
11/05/20 Piper Sandler
Regeneron shares will continue moving higher, says Piper Sandler
HGEN Humanigen
$8.88 /

+0.61 (+7.38%)

11/06/20 H.C. Wainwright
Humanigen price target raised to $34 from $31 at H.C. Wainwright
10/21/20
Fly Intel: Top five analyst initiations
10/21/20 Cantor Fitzgerald
Humanigen initiated with an Overweight at Cantor Fitzgerald
10/20/20 Cantor Fitzgerald
Humanigen initiated with an Overweight at Cantor Fitzgerald
REGN Regeneron
$519.36 /

+4.81 (+0.93%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

HGEN Humanigen
$8.88 /

+0.61 (+7.38%)

GILD Gilead
$60.10 /

-0.53 (-0.87%)

  • 18
    Sep
  • 27
    May
REGN Regeneron
$519.36 /

+4.81 (+0.93%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

GILD Gilead
$60.10 /

-0.53 (-0.87%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

HGEN Humanigen
$8.88 /

+0.61 (+7.38%)

GILD Gilead
$60.10 /

-0.53 (-0.87%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

HGEN Humanigen
$8.88 /

+0.61 (+7.38%)

GILD Gilead
$60.10 /

-0.53 (-0.87%)

Sunday
Hot Stocks
Fly Intel: Top five weekend stock stories » 19:32
11/22/20
11/22
19:32
11/22/20
19:32
REGN

Regeneron

$519.36 /

+4.81 (+0.93%)

, CSGP

CoStar Group

$890.12 /

-4.23 (-0.47%)

, BA

Boeing

$199.62 /

-6.01 (-2.92%)

, BX

Blackstone

$58.64 /

-0.005 (-0.01%)

, WMT

Walmart

$150.31 /

-1.91 (-1.25%)

, AMZN

Amazon.com

$3,099.48 /

-18.91 (-0.61%)

, FITB

Fifth Third

$25.28 /

-0.6 (-2.32%)

, HBAN

Huntington Bancshares

$11.76 /

-0.19 (-1.59%)

, SPG

Simon Property

$81.13 /

+0.46 (+0.57%)

, CFG

Citizens Financial

$32.29 /

-0.51 (-1.55%)

, SNV

Synovus

$30.87 /

-0.1 (-0.32%)

, TFC

Truist Financial

$46.21 /

-0.625 (-1.33%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Regeneron Pharmaceuticals (REGN) announced that the antibody cocktail casirivimab and imdevimab administered together, a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization from the Food and Drug Administration. Casirivimab and imdevimab administered together are authorized for the treatment of mild to moderate COVID-19 in adults, as well as in pediatric patients at least 12 years of age and weighing at least 40 kg, who have received positive results of direct SARS-CoV-2 viral testing and are at high risk for progressing to severe COVID-19 and/or hospitalization. Regeneron expects to have REGEN-COV2 treatment doses ready for approximately 80,000 patients by the end of November, approximately 200,000 patients by the first week of January, and approximately 300,000 patients in total by the end of January 2021. 2. CoStar Group (CSGP) announced that it has reached an agreement to acquire Homesnap for $250M in cash. "The acquisition of Homesnap will enable us to enter a new space and expand the total addressable markets in which we can compete," said CoStar Group founder and CEO, Andy Florance. "The estimated value of commercial real estate assets in the U.S. is $16 trillion. With the new addition of clients and information covering 90% of the estimated $27 trillion dollar U.S. residential real estate market we are almost tripling the size of our addressable markets." 3. The return of Boeing's (BA) 737 MAX was supposed to bring clarity for investors, and yet it has done anything but, Al Root wrote in this week's edition of Barron's. There are certainly tough days ahead for Boeing, with air-travel demand still a fraction of what it was pre-pandemic, and Boeing's net debt ballooning to about $34B from $8B before the second crash, the author noted. Cash flow and profit margins will be affected by the MAX mess for years. But a lot of bad news is already reflected in the shares, the publication added. 4. Blackstone (BX) is doubling down on Asia, seeking to raise at least $5B for its second private equity fund focused on the region, Bloomberg's Cathy Chan and Baiju Kalesh reported, citing people familiar with the matter. 5. Walmart (WMT), Amazon.com (AMZN), Simon Property Group (SPG), Huntington Bancshares (HBAN), Fifth Third Bancorp (FITB), Citizens Financial (CFG), Synovus Financial (SNV), Truist Financial (TFC) saw positive mentions in this week's edition of Barron's.

ShowHide Related Items >><<
WMT Walmart
$150.31 /

-1.91 (-1.25%)

TFC Truist Financial
$46.21 /

-0.625 (-1.33%)

SPG Simon Property
$81.13 /

+0.46 (+0.57%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

HBAN Huntington Bancshares
$11.76 /

-0.19 (-1.59%)

FITB Fifth Third
$25.28 /

-0.6 (-2.32%)

CSGP CoStar Group
$890.12 /

-4.23 (-0.47%)

CFG Citizens Financial
$32.29 /

-0.51 (-1.55%)

BX Blackstone
$58.64 /

-0.005 (-0.01%)

BA Boeing
$199.62 /

-6.01 (-2.92%)

AMZN Amazon.com
$3,099.48 /

-18.91 (-0.61%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
11/06/20 Truist
Regeneron price target raised to $770 from $750 at Truist
11/05/20 Piper Sandler
Regeneron shares will continue moving higher, says Piper Sandler
CSGP CoStar Group
$890.12 /

-4.23 (-0.47%)

10/28/20 Truist
CoreLogic could be sold for 'meaningfully more' than $80 per share, says Truist
10/28/20 Needham
CoStar Group price target raised to $1,000 from $825 at Needham
10/28/20 Truist
CoStar Group price target raised to $1,000 from $850 at Truist
10/28/20 JMP Securities
CoStar Group price target raised to $950 from $800 at JMP Securities
BA Boeing
$199.62 /

-6.01 (-2.92%)

11/19/20 Susquehanna
Boeing price target raised to $275 from $220 at Susquehanna
11/18/20 Goldman Sachs
Boeing price target raised to $245 from $231 at Goldman Sachs
11/18/20 William Blair
Boeing 737 Max approval 'a modest positive' for ViaSat, says William Blair
11/18/20
Fly Intel: Top five analyst upgrades
BX Blackstone
$58.64 /

-0.005 (-0.01%)

10/29/20 Oppenheimer
Blackstone upgraded to Outperform at Oppenheimer
10/29/20 Oppenheimer
Blackstone upgraded to Outperform from Perform at Oppenheimer
06/25/20
Fly Intel: Top five analyst initiations
06/25/20 UBS
Blackstone initiated with a Buy at UBS
WMT Walmart
$150.31 /

-1.91 (-1.25%)

11/18/20 Raymond James
Walmart price target raised to $165 from $145 at Raymond James
11/18/20 DA Davidson
Walmart price target raised to $177 from $154 at DA Davidson
11/18/20 BMO Capital
Walmart price target raised to $175 from $160 at BMO Capital
11/18/20 MKM Partners
Walmart price target raised to $154 from $147 at MKM Partners
AMZN Amazon.com
$3,099.48 /

-18.91 (-0.61%)

11/20/20 Credit Suisse
GoodRx price target lowered to $49 from $60 at Credit Suisse
11/19/20 Pivotal Research
Pivotal Research upgrades Roku to Hold with lead seeming sustainable
11/19/20 Credit Suisse
Credit Suisse remains bullish on Amazon ahead of quarterly results
11/19/20 RBC Capital
GoodRx upgraded to Outperform from Sector Perform at RBC Capital
FITB Fifth Third
$25.28 /

-0.6 (-2.32%)

10/30/20 UBS
Fifth Third downgraded to Neutral from Buy at UBS
10/23/20 Janney Montgomery Scott
Fifth Third upgraded to Buy from Neutral at Janney Montgomery Scott
10/12/20 Citi
Citi initiates pair trade of long KeyCorp, short Fifth Third
10/06/20 JPMorgan
Fifth Third price target raised to $24 from $20.50 at JPMorgan
HBAN Huntington Bancshares
$11.76 /

-0.19 (-1.59%)

10/26/20
Fly Intel: Top five analyst upgrades
10/26/20 Wedbush
Huntington Bancshares upgraded to Outperform at Wedbush
10/26/20 Wedbush
Huntington Bancshares upgraded to Outperform from Neutral at Wedbush
07/31/20 Wolfe Research
Huntington Bancshares initiated with an Outperform at Wolfe Research
SPG Simon Property
$81.13 /

+0.46 (+0.57%)

11/17/20 Compass Point
Macerich upgraded to Buy following peer's revised deal at Compass Point
11/16/20 Mizuho
Simon Property price target raised to $74 from $66 at Mizuho
11/16/20 Piper Sandler
Taubman Centers upgraded to Neutral from Underweight at Piper Sandler
11/11/20 Wells Fargo
Simon Property price target raised to $80 from $70 at Wells Fargo
CFG Citizens Financial
$32.29 /

-0.51 (-1.55%)

11/18/20 Keefe Bruyette
Citizens Financial downgraded to Market Perform at Keefe Bruyette
10/18/20 Keefe Bruyette
Citizens Financial post-earnings selloff overdone, says Keefe Bruyette
10/06/20 JPMorgan
Citizens Financial price target raised to $29.50 from $25.50 at JPMorgan
SNV Synovus
$30.87 /

-0.1 (-0.32%)

11/10/20 Janney Montgomery Scott
Synovus downgraded to Neutral from Buy at Janney Montgomery Scott
10/22/20
Fly Intel: Top five analyst upgrades
10/22/20 Stephens
Synovus upgraded to Overweight following earnings at Stephens
10/22/20 Stephens
Synovus upgraded to Overweight from Equal Weight at Stephens
TFC Truist Financial
$46.21 /

-0.625 (-1.33%)

11/18/20 Keefe Bruyette
Truist Financial downgraded to Market Perform from Outperform at Keefe Bruyette
10/16/20 Argus
Truist Financial price target raised to $48 from $45 at Argus
10/06/20 JPMorgan
Truist Financial price target raised to $43.50 from $40 at JPMorgan
07/31/20 Wolfe Research
Truist Financial initiated with an Outperform at Wolfe Research
WMT Walmart
$150.31 /

-1.91 (-1.25%)

TFC Truist Financial
$46.21 /

-0.625 (-1.33%)

SPG Simon Property
$81.13 /

+0.46 (+0.57%)

SNV Synovus
$30.87 /

-0.1 (-0.32%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

HBAN Huntington Bancshares
$11.76 /

-0.19 (-1.59%)

FITB Fifth Third
$25.28 /

-0.6 (-2.32%)

CSGP CoStar Group
$890.12 /

-4.23 (-0.47%)

CFG Citizens Financial
$32.29 /

-0.51 (-1.55%)

BX Blackstone
$58.64 /

-0.005 (-0.01%)

BA Boeing
$199.62 /

-6.01 (-2.92%)

AMZN Amazon.com
$3,099.48 /

-18.91 (-0.61%)

  • 19
    Nov
  • 27
    May
  • 21
    May
WMT Walmart
$150.31 /

-1.91 (-1.25%)

TFC Truist Financial
$46.21 /

-0.625 (-1.33%)

SPG Simon Property
$81.13 /

+0.46 (+0.57%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

FITB Fifth Third
$25.28 /

-0.6 (-2.32%)

CSGP CoStar Group
$890.12 /

-4.23 (-0.47%)

BX Blackstone
$58.64 /

-0.005 (-0.01%)

BA Boeing
$199.62 /

-6.01 (-2.92%)

AMZN Amazon.com
$3,099.48 /

-18.91 (-0.61%)

WMT Walmart
$150.31 /

-1.91 (-1.25%)

TFC Truist Financial
$46.21 /

-0.625 (-1.33%)

SPG Simon Property
$81.13 /

+0.46 (+0.57%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

HBAN Huntington Bancshares
$11.76 /

-0.19 (-1.59%)

FITB Fifth Third
$25.28 /

-0.6 (-2.32%)

CSGP CoStar Group
$890.12 /

-4.23 (-0.47%)

CFG Citizens Financial
$32.29 /

-0.51 (-1.55%)

BX Blackstone
$58.64 /

-0.005 (-0.01%)

BA Boeing
$199.62 /

-6.01 (-2.92%)

AMZN Amazon.com
$3,099.48 /

-18.91 (-0.61%)

WMT Walmart
$150.31 /

-1.91 (-1.25%)

SPG Simon Property
$81.13 /

+0.46 (+0.57%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

HBAN Huntington Bancshares
$11.76 /

-0.19 (-1.59%)

FITB Fifth Third
$25.28 /

-0.6 (-2.32%)

CFG Citizens Financial
$32.29 /

-0.51 (-1.55%)

BX Blackstone
$58.64 /

-0.005 (-0.01%)

BA Boeing
$199.62 /

-6.01 (-2.92%)

AMZN Amazon.com
$3,099.48 /

-18.91 (-0.61%)

Hot Stocks
Regeneron receives Emergency Use Authorization for Covid antibody cocktail » 08:47
11/22/20
11/22
08:47
11/22/20
08:47
REGN

Regeneron

$519.36 /

+4.81 (+0.93%)

Regeneron Pharmaceuticals…

Regeneron Pharmaceuticals announced that the antibody cocktail casirivimab and imdevimab administered together, a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization from the Food and Drug Administration. Casirivimab and imdevimab administered together are authorized for the treatment of mild to moderate COVID-19 in adults, as well as in pediatric patients at least 12 years of age and weighing at least 40 kg, who have received positive results of direct SARS-CoV-2 viral testing and are at high risk for progressing to severe COVID-19 and/or hospitalization. "The clinical evidence from Regeneron's outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load," Regeneron said in a statement. Regeneron expects to have REGEN-COV2 treatment doses ready for approximately 80,000 patients by the end of November, approximately 200,000 patients by the first week of January, and approximately 300,000 patients in total by the end of January 2021. REGEN-COV2 continues to be evaluated in Phase 2/3 clinical trials for the treatment of COVID-19 in certain hospitalized and non-hospitalized patients, the Phase 3 open-label RECOVERY trial of hospitalized patients in the UK, and a Phase 3 trial for the prevention of COVID-19 in household contacts of infected individuals. To date, more than 7,000 people have participated in REGEN-COV2 clinical trials.

ShowHide Related Items >><<
REGN Regeneron
$519.36 /

+4.81 (+0.93%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
11/06/20 Truist
Regeneron price target raised to $770 from $750 at Truist
11/05/20 Piper Sandler
Regeneron shares will continue moving higher, says Piper Sandler
REGN Regeneron
$519.36 /

+4.81 (+0.93%)

  • 27
    May
REGN Regeneron
$519.36 /

+4.81 (+0.93%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

Saturday
On The Fly
Week in review: How Trump's policies moved stocks » 09:03
11/21/20
11/21
09:03
11/21/20
09:03
REGN

Regeneron

$519.36 /

+4.81 (+0.93%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, IFNNY

Infineon

$0.00 /

+ (+0.00%)

, AZN

AstraZeneca

$55.29 /

+1.27 (+2.35%)

, BMY

Bristol-Myers

$61.62 /

-0.47 (-0.76%)

, LLY

Eli Lilly

$145.62 /

+2.16 (+1.51%)

, GSK

GlaxoSmithKline

$37.03 /

-0.11 (-0.30%)

, JNJ

Johnson & Johnson

$146.33 /

-0.76 (-0.52%)

, MRK

Merck

$80.46 /

+0.04 (+0.05%)

, NVS

Novartis

$87.51 /

+0.285 (+0.33%)

, PFE

Pfizer

$36.70 /

+0.51 (+1.41%)

, SNY

Sanofi

$50.47 /

-0.34 (-0.67%)

Catch up on the top…

ShowHide Related Items >><<
SNY Sanofi
$50.47 /

-0.34 (-0.67%)

RHHBY Roche
$0.00 /

+ (+0.00%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

PFE Pfizer
$36.70 /

+0.51 (+1.41%)

NVS Novartis
$87.51 /

+0.285 (+0.33%)

MRK Merck
$80.46 /

+0.04 (+0.05%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

JNJ Johnson & Johnson
$146.33 /

-0.76 (-0.52%)

IFNNY Infineon
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.62 /

-0.47 (-0.76%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
11/06/20 Truist
Regeneron price target raised to $770 from $750 at Truist
11/05/20 Piper Sandler
Regeneron shares will continue moving higher, says Piper Sandler
RHHBY Roche
$0.00 /

+ (+0.00%)

10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
IFNNY Infineon
$0.00 /

+ (+0.00%)

11/10/20 Morgan Stanley
Infineon price target raised to EUR 30.50 from EUR 30 at Morgan Stanley
11/10/20 Deutsche Bank
Infineon price target raised to EUR 33 from EUR 27 at Deutsche Bank
11/05/20 Credit Suisse
Infineon price target raised to EUR 22.50 from EUR 19.20 at Credit Suisse
10/26/20 Morgan Stanley
Infineon price target raised to EUR 30 from EUR 25 at Morgan Stanley
AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

11/11/20 Oppenheimer
Amgen price target raised to $280 from $275 at Oppenheimer
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
BMY Bristol-Myers
$61.62 /

-0.47 (-0.76%)

11/17/20 Mizuho
Bristol-Myers Squibb CVR price target lowered to $3.34 from $6.17 at Mizuho
11/16/20 Societe Generale
Bristol-Myers upgraded to Buy from Hold at Societe Generale
11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein
11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform at Bernstein
LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

11/20/20 Stifel
Precision BioSciences price target raised to $22 from $21 at Stifel
11/17/20 Mizuho
Eli Lilly price target lowered to $156 from $164 at Mizuho
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform, $150 price target at Bernstein
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform at Bernstein
GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

11/13/20 Morgan Stanley
GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/20 Liberum
GlaxoSmithKline upgraded to Buy from Hold at Liberum
10/30/20 Barclays
GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays
10/27/20 Truist
AnaptysBio price target raised to $27 from $20 at Truist
JNJ Johnson & Johnson
$146.33 /

-0.76 (-0.52%)

11/12/20 Chardan
Immunovant price target raised to $60 from $45 at Chardan
11/10/20 Piper Sandler
Aligos Therapeutics initiated with an Overweight at Piper Sandler
10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
10/14/20 Credit Suisse
Johnson & Johnson price target raised to $168 from $163 at Credit Suisse
MRK Merck
$80.46 /

+0.04 (+0.05%)

11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
10/23/20
Fly Intel: Pre-market Movers
NVS Novartis
$87.51 /

+0.285 (+0.33%)

11/10/20 JPMorgan
Novartis price target raised to CHF 85 from CHF 82 at JPMorgan
10/26/20 JMP Securities
Kura Oncology price target raised to $33 from $22 at JMP Securities
09/29/20 Berenberg
Novartis initiated with a Buy at Berenberg
09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
PFE Pfizer
$36.70 /

+0.51 (+1.41%)

11/19/20
Fly Intel: Top five analyst initiations
11/19/20 Goldman Sachs
Pfizer reinstated with a Neutral at Goldman Sachs
11/17/20 Benchmark
Inovio on 'top-10 vaccine contenders list,' says Benchmark
11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
SNY Sanofi
$50.47 /

-0.34 (-0.67%)

11/03/20 Morgan Stanley
Sanofi price target lowered to EUR 105 from EUR 107 at Morgan Stanley
10/30/20 JPMorgan
Sanofi price target lowered to EUR 100 from EUR 106 at JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
SNY Sanofi
$50.47 /

-0.34 (-0.67%)

RHHBY Roche
$0.00 /

+ (+0.00%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

PFE Pfizer
$36.70 /

+0.51 (+1.41%)

NVS Novartis
$87.51 /

+0.285 (+0.33%)

MRK Merck
$80.46 /

+0.04 (+0.05%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

JNJ Johnson & Johnson
$146.33 /

-0.76 (-0.52%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.62 /

-0.47 (-0.76%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

  • 27
    May
SNY Sanofi
$50.47 /

-0.34 (-0.67%)

RHHBY Roche
$0.00 /

+ (+0.00%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

PFE Pfizer
$36.70 /

+0.51 (+1.41%)

NVS Novartis
$87.51 /

+0.285 (+0.33%)

MRK Merck
$80.46 /

+0.04 (+0.05%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

JNJ Johnson & Johnson
$146.33 /

-0.76 (-0.52%)

IFNNY Infineon
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.62 /

-0.47 (-0.76%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

SNY Sanofi
$50.47 /

-0.34 (-0.67%)

RHHBY Roche
$0.00 /

+ (+0.00%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

PFE Pfizer
$36.70 /

+0.51 (+1.41%)

NVS Novartis
$87.51 /

+0.285 (+0.33%)

MRK Merck
$80.46 /

+0.04 (+0.05%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

JNJ Johnson & Johnson
$146.33 /

-0.76 (-0.52%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.62 /

-0.47 (-0.76%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

PFE Pfizer
$36.70 /

+0.51 (+1.41%)

MRK Merck
$80.46 /

+0.04 (+0.05%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

JNJ Johnson & Johnson
$146.33 /

-0.76 (-0.52%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.62 /

-0.47 (-0.76%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.